Amarin (AMRN) CEO Aaron Berg Reports New Equity Awards on Form 4

Rhea-AI Filing Summary

On 26 June 2025, Amarin Corp. (AMRN) President & CEO Aaron Berg filed a Form 4 detailing routine executive-compensation transactions.

• 75,000 American Depositary Shares (ADS) were issued upon the automatic conversion of vested restricted stock units (code M).
• 38,363 ADS were withheld by the issuer to satisfy tax obligations (code F), leaving a net increase of 36,637 ADS.
• Berg’s direct ownership after the transactions stands at 80,714 ADS.
• New equity awards granted on the same date include:
  • 37,500 stock options with a strike price of $15.90, vesting 50 % after one year and the remainder 18 months from grant.
  • 75,000 RSUs that vested immediately.
  • 12,500 RSUs vesting in two equal instalments—first anniversary and 18 months post-grant.
• The filing reflects the 1 ADS = 20 ordinary shares ratio change implemented on 11 April 2025.

No open-market purchases or sales were reported; the activity is compensation-related and does not materially affect Amarin’s capital structure.

Insights

Securities Analyst

TL;DR Routine equity grants and tax withholding; no open-market activity—overall neutral for AMRN valuation.

The Form 4 shows standard incentive awards: immediate-vesting RSUs, deferred RSUs, and stock options at a market-aligned $15.90 strike. While the CEO’s direct stake rises by roughly 36.6 k ADS, the shares stem from equity compensation rather than discretionary buying, limiting bullish interpretation. Dilution is immaterial relative to Amarin’s share count, and the option/RSU mix aligns management with shareholder outcomes. Overall, the disclosure neither alters the investment thesis nor signals directional insight.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Berg Aaron

(Last) (First) (Middle)

C/O AMARIN PHARMA, INC.

440 US HIGHWAY 22

(Street)

BRIDGEWATER NJ 08807

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AMARIN CORP PLC\UK [ AMRN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
American Depositary Share(1)	06/26/2025		M(2)		75,000(1)	A	(3)	119,077(1)	D
American Depositary Share(1)	06/26/2025		F(4)		38,363(1)	D	$15.9	80,714(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$15.9	06/26/2025		A		37,500(1)		(5)	06/26/2035	American Depositary Shares(1)	37,500(1)	$0.00	37,500(1)	D
Restricted Stock Unit(6)	$0.00	06/26/2025		A(7)		75,000(1)		(2)	(3)	American Depositary Shares(1)	75,000(1)	$0.00	0(1)	D
Restricted Stock Unit(6)	$0.00	06/26/2025		A		12,500(1)		(8)	(3)	American Depositary Shares(1)	12,500	$0.00	12,500(1)	D

Explanation of Responses:

1. Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change.

2. On June 26, 2025 the Reporting Person was granted 75,000 RSUs that vested as of the June 26, 2025.

3. Not applicable.

4. Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities.

5. On June 26, 2025 the Reporting Person was granted an option to purchase 37,500 American Depositary Shares ("ADS") under the Plan. The shares subject to this option shall vest and become exercisable over eighteen months, with 50% to vest on the first anniversary of the grant date and the remaining balance to vest eighteen months after grant date.

6. Each RSU represents a contingent right to receive twenty Ordinary Shares or cash in lieu thereof at the Issuer's discretion.

7. Additionally, award was exercise or conversion of derivative security exempted pursuant to Rule 16b-3.

8. On June 26, 2025, the Reporting Person was granted 12,500 RSUs that vests in two equal installments on the first anniversary of the grant date and the remaining balance to vest eighteen months after grant date.

	/s/ Jonathan Provoost, by power of attorney	06/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many ADS did AMRN CEO Aaron Berg acquire on 26 June 2025?

He acquired 75,000 ADS through vesting of restricted stock units.

What is the exercise price of the new stock options granted to Berg?

The options have an exercise price of $15.90 per ADS.

How many ADS does Aaron Berg own after the reported transactions?

His direct ownership totals 80,714 ADS following the transactions.

What is the vesting schedule for the 12,500 newly granted RSUs?

They vest in two equal installments: 50 % after one year and the remaining 50 % at 18 months.

Why were 38,363 ADS disposed of in the filing?

Those shares were withheld to cover tax liabilities arising from RSU vesting—no market sale occurred.